Aytu BioPharma ends Metadate CD license deal
Aytu BioPharma, Inc. has mutually agreed with Lannett Company, Inc. to terminate their exclusive license agreement for Metadate CD, effective June 23, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Aytu BioPharma, Inc. has mutually agreed with Lannett Company, Inc. to terminate their exclusive license agreement for Metadate CD, effective June 23, 2026. This ends Aytu’s licensed rights under the Metadate Agreement, except for certain surviving provisions described in a separate Termination Agreement.
Aytu may continue to sell and distribute its remaining Metadate CD inventory at its own discretion and must keep providing royalty reports and paying related royalties until those inventory sales stop. Net revenue from Metadate CD reported for the quarter ended March 31, 2026 was $49,000, indicating the product’s relatively modest contribution before termination.
8-K Event Classification
Item 1.02 — Termination of a Material Definitive Agreement
1 item
Item 1.02
Termination of a Material Definitive Agreement
Business
A significant contract was terminated, which may affect business operations or revenue.
Key Figures
Metadate CD net revenue: $49,000
Metadate Agreement termination date: June 23, 2026
Original Metadate Agreement date: May 11, 2022
+2 more
5 metrics
Metadate CD net revenue
$49,000
Quarter ended March 31, 2026
Metadate Agreement termination date
June 23, 2026
Effective termination of exclusive license
Original Metadate Agreement date
May 11, 2022
Exclusive license agreement execution date
First amendment date
July 6, 2023
Amendment to Metadate Agreement
Second amendment date
July 17, 2025
Second amendment to Metadate Agreement
Key Terms
Material Definitive Agreement, Termination Agreement, exclusive license agreement, Net revenue of Metadate CD
4 terms
Material Definitive Agreement regulatory
"Item 1.02 Termination of Material Definitive Agreement."
A material definitive agreement is a legally binding contract that creates major, long‑term obligations or rights for a company, such as loans, asset sales, mergers, or supplier deals. Think of it like a mortgage or lease for a business: it can change future cash flow, risk and control, so investors watch these agreements closely because they can materially affect a company’s value, financial health and stock price.
Termination Agreement regulatory
"the Company entered into a Termination Agreement (the “Termination Agreement”) with Lannett."
A termination agreement is a written contract that formally ends a prior agreement between two or more parties and sets the terms for how obligations, payments, and rights are resolved when that relationship stops. It matters to investors because it can change a company’s future cash flows, liabilities, legal exposure and access to assets or services—like the paperwork you sign when you break a lease that also settles who pays what and who keeps what.
exclusive license agreement financial
"that certain exclusive license agreement entered into by the parties on May 11, 2022"
An exclusive license agreement is a legal deal in which the owner of an asset—like a patent, technology, or drug formula—grants only one other party the right to use, make, sell, or further develop that asset. For investors, it matters because exclusivity can create a predictable revenue stream or competitive edge for the licensee, while limiting the owner’s ability to monetize the asset elsewhere; think of it as giving one vendor sole rights to sell a popular product in a market.
Net revenue of Metadate CD financial
"Net revenue of Metadate CD® reported by the Company for the Quarter Ended March 31, 2026 was $49,000."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Aytu BioPharma (AYTU) announce in this Form 8-K?
Aytu BioPharma announced that it mutually agreed with Lannett Company to terminate their exclusive license agreement for Metadate CD, effective June 23, 2026, while keeping certain provisions in place under a separate Termination Agreement.
When did the Metadate CD license agreement between AYTU and Lannett end?
The exclusive license agreement for Metadate CD between Aytu BioPharma and Lannett terminated effective June 23, 2026. Both parties agreed to end the arrangement and documented the details in a Termination Agreement that governs remaining obligations.
Can Aytu BioPharma (AYTU) still sell Metadate CD after the termination?
Aytu BioPharma can continue to sell and distribute its existing Metadate CD inventory at its sole discretion. The company must keep providing royalty reports and paying certain royalties on those sales until its remaining Metadate CD inventory is fully sold.
How much revenue did AYTU report from Metadate CD before terminating the deal?
Aytu BioPharma reported net revenue of $49,000 from Metadate CD for the quarter ended March 31, 2026. This figure shows the product’s relatively small revenue contribution ahead of the mutual termination of the underlying license agreement.
Where can investors find the full Metadate Termination Agreement for AYTU?
The full Termination Agreement between Aytu BioPharma and Lannett will be filed as an exhibit to Aytu’s Annual Report on Form 10-K for the year ended June 30, 2026, providing complete legal terms beyond the brief summary disclosed here.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
(Address of principal executive offices, including zip code)
(720 ) 437-6580
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered |
||
The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.02 Termination of Material Definitive Agreement.
On June 23, 2026, Aytu BioPharma, Inc. (the “Company”) and Lannett Company, Inc. (together with its affiliates, “Lannett”) mutually agreed to terminate, effective as of June 23, 2026, that certain exclusive license agreement entered into by the parties on May 11, 2022, as amended on July 6, 2023, and July 17, 2025 (collectively, the “Metadate Agreement”).
In connection with the termination of the Metadate Agreement, the Company entered into a Termination Agreement (the “Termination Agreement”) with Lannett. Pursuant to the terms of the Termination Agreement, the Metadate Agreement is terminated in its entirety, except for certain provisions that survive the termination as specified in the Termination Agreement.
Pursuant to the terms of the Metadate Agreement, the Company may continue to sell and distribute existing inventory at its sole discretion and shall continue to provide certain royalty reports and pay certain royalties until such sales cease.
Net revenue of Metadate CD® reported by the Company for the Quarter Ended March 31, 2026 was $49,000.
The description of the Termination Agreement in this Current Report on Form 8-K does not purport to be complete and is qualified in its entirety by reference to the full text of the Termination Agreement, which will be filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ended June 30, 2026.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AYTU BIOPHARMA, INC. |
||
Date: June 25, 2026 | By: | /s/ Ryan J. Selhorn |
Ryan J. Selhorn |
||
Chief Financial Officer |
||